Therefore, the status of PD-L1 was not involved to construct the combined machine learning model with clinicopathological information in the study because PD-L1 was usually assessed for NSCLC with immune checkpoint inhibitor treatment-based NAT. This evidence concerns the gene CD274 and non-small cell lung carcinoma.